Slate Path Capital LP Arrowhead Pharmaceuticals, Inc. Transaction History
Slate Path Capital LP
- $5.01 Billion
- Q2 2025
A detailed history of Slate Path Capital LP transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Slate Path Capital LP holds 5,232,000 shares of ARWR stock, worth $181 Million. This represents 1.65% of its overall portfolio holdings.
Number of Shares
5,232,000
Previous 5,232,000
-0.0%
Holding current value
$181 Million
Previous $66.7 Million
24.02%
% of portfolio
1.65%
Previous 1.32%
Shares
4 transactions
Others Institutions Holding ARWR
# of Institutions
321Shares Held
99.1MCall Options Held
444KPut Options Held
568K-
Black Rock Inc. New York, NY15.7MShares$543 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.5MShares$537 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY10.6MShares$367 Million3.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$220 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.98MShares$103 Million0.0% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $3.66B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...